2026年欧洲肝脏病学会肝癌峰会（Liver Cance)

亲爱的朋友们，我们回来了！比以往更强大！ 

EASL肝癌峰会无疑已成为所有肝癌患者及相关研究工作者年度“必参加”的盛会。肝病学家、肿瘤学家、介入放射科医生、外科医生、病理学家、科学家、护士以及患者将齐聚美丽的爱丁堡，共同更新和巩固我们的知识，并为患者提供最佳的治疗方案。 

我们正在见证肝细胞癌和胆管癌治疗方案发展中的一场真正革命，这比以往任何时候都更需要我们共同努力来理解和管理这些肿瘤的复杂性。为此，基础研究、转化研究和临床研究正在携手合作，以解决尚未解决的医疗需求。 

这是一个与不同学科的同行交流的独特机会，可以制定流行病学、分子发病机制和肝肿瘤管理最新知识（包括手术、局部区域治疗、全身治疗）的当前标准，深入研究个性化医疗的复杂性，并预见这个快速变化和发展的领域的未来挑战和机遇。 

基础科学、临床管理、医疗资源、患者权益以及热点话题争议：所有这些以及更多内容都在等待您在 2026 年 1 月 22 日至 24 日在爱丁堡举行的 EASL 肝癌峰会上做出贡献。  

2026年EASL肝癌峰会组织者

EASL Liver 2026

EASL Liver Cancer Summit 2026 Scientific Programme

The 2026 EASL Liver Cancer Summit in Edinburgh will present the latest in liver cancer research and clinical care. 

Day 1 focuses on the link between MASLD and HCC, advances in surveillance methods and blood-based biomarkers, and cutting-edge tools like spatial transcriptomics and AI. Sessions will also explore the molecular pathogenesis of HCC and cholangiocarcinoma, highlighting emerging targets and innovative therapies. 

Day 2 covers evolving strategies in liver cancer surgery, transplantation, and neoadjuvant treatments. It includes updates from pivotal Phase III trials, developments in locoregional therapies such as TACE and TARE, and debates on staging systems, SBRT, and the role of palliative care. The day also features oral presentations on recent research. 

Day 3 explores systemic therapies for HCC, including treatment sequencing, immunotherapy selection, and care for patients with impaired liver function. The closing session looks ahead to biomarker-driven therapy, healthcare equity, and patient-centred care in liver oncology. 

Join leading experts from across disciplines to shape the future of liver cancer treatment from 22–24 January 2026 in Edinburgh.